HomeCompareTBVPY vs ABBV

TBVPY vs ABBV: Dividend Comparison 2026

TBVPY yields 4.86% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBVPY wins by $229.9K in total portfolio value· pulled ahead in Year 4
10 years
TBVPY
TBVPY
● Live price
4.86%
Share price
$33.46
Annual div
$1.63
5Y div CAGR
44.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$332.3K
Annual income
$162,779.31
Full TBVPY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TBVPY vs ABBV

📍 TBVPY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBVPYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBVPY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TBVPY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBVPY
Annual income on $10K today (after 15% tax)
$413.08/yr
After 10yr DRIP, annual income (after tax)
$138,362.41/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TBVPY beats the other by $117,306.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBVPY + ABBV for your $10,000?

TBVPY: 50%ABBV: 50%
100% ABBV50/50100% TBVPY
Portfolio after 10yr
$217.3K
Annual income
$93,775.54/yr
Blended yield
43.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TBVPY
No analyst data
Altman Z
2.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBVPY buys
0
ABBV buys
0
No recent congressional trades found for TBVPY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBVPYABBV
Forward yield4.86%3.06%
Annual dividend / share$1.63$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR44.2%40.6%
Portfolio after 10y$332.3K$102.3K
Annual income after 10y$162,779.31$24,771.77
Total dividends collected$292.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TBVPY vs ABBV ($10,000, DRIP)

YearTBVPY PortfolioTBVPY Income/yrABBV PortfolioABBV Income/yrGap
1$11,401$700.77$11,550$430.00$149.00ABBV
2$13,276$1,076.70$13,472$627.96$196.00ABBV
3$15,894$1,689.64$15,906$926.08$12.00ABBV
4← crossover$19,733$2,726.27$19,071$1,382.55+$662.00TBVPY
5$25,676$4,561.47$23,302$2,095.81+$2.4KTBVPY
6$35,472$7,998.63$29,150$3,237.93+$6.3KTBVPY
7$52,847$14,892.04$37,536$5,121.41+$15.3KTBVPY
8$86,446$29,899.97$50,079$8,338.38+$36.4KTBVPY
9$158,412$65,914.00$69,753$14,065.80+$88.7KTBVPY
10$332,280$162,779.31$102,337$24,771.77+$229.9KTBVPY

TBVPY vs ABBV: Complete Analysis 2026

TBVPYStock

Thai Beverage Public Company Limited, together with its subsidiaries, produces and distributes alcoholic and non-alcoholic beverages, and food products worldwide. It operates through Spirits, Beer, Non-Alcoholic Beverages, and Food segments. The company offers liquor, beer, malt, and yeast products; spirits, including brown spirits, white spirits, herbs, and other products; and non-alcoholic beverages comprising drinking and soda water, electrolyte beverages, energy drinks, green and herbal tea, ready-to-drink coffee, fruit flavored drinks, and soft drinks; carbonated soft drinks, tea, isotonics, soya drinks, Asian and sparkling drinks, cordials, water, pasteurized milk, UHT milk, sterilized milk, yoghurt, canned milk, pasteurized juice, ready-to-drink juice, ice cream, and cereal bars. The company also provides chilled and frozen food products; and fertilizers, feeds, bricks, and oak barrels. In addition, it is involved in the trading of molasses; provision of transportation and distribution, logistics, advertising and marketing, consultancy, asset and brands management, public cold storage, and human resources and organization development services; operation of restaurants, bakeries, and social enterprise; and production and distribution of biogas. Further, the company engages in the trading of bottles and supplies; wholesale and distribution of beverages; and production of metal and plastic packaging businesses. Additionally, it engages in asset management activities; trademark holding and production of beer concentrates; e-commerce business; offers marketing management consulting and data analytics solutions; development, rental, and investment in properties; mechanical equipment manufacturing; warehousing business; trading of chemical and packaging materials; manufacture of equipment used in food manufacturing; and installation and maintenance of machinery system and equipment. The company was incorporated in 2003 and is based in Bangkok, Thailand.

Full TBVPY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TBVPY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBVPY vs SCHDTBVPY vs JEPITBVPY vs OTBVPY vs KOTBVPY vs MAINTBVPY vs JNJTBVPY vs MRKTBVPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.